EyePoint Pharmaceuticals’ CEO on treating serious eye disorders and female leadership in life sciences

EyePoint Pharmaceuticals (NASDAQ: EYPT) specializes in creating ocular products for serious eye disorders. The company has developed five FDA-approved sustained-release treatments in ophthalmology. The company’s preclinical development program is focused on drug candidates to treat wet age-related macular degeneration, glaucoma, osteoarthritis and other diseases.

The company was formed in 2018 after pSivida announced acquired Icon Bioscience.

To learn more about the company, we interviewed EyePoint Pharmaceuticals’ president and CEO, Nancy S. Lurker, who is also an advisor to Novo Nordisk and serves on the board of directors for the company Aquestive Therapeutics.

In the following interview, Lurker touches on what inspires her as the CEO of EyePoint while also providing advice for women interested in pursuing leadership roles within the life sciences industry.

Nancy Lurker

Preventing bli…

Read more
  • 0

Novartis shares dip after announcing disappointing Q4 results

Novartis (NYSE:NVS) posted fourth-quarter results today that trailed the consensus forecast.

The Basel, Switzerland–based company reported a $2.1 billion net income, an 86% increase in Q4 2019. Earnings per share for the quarter ended Dec. 31 were $1.34 per share on revenue of $12.8 billion. 

Analysts had anticipated earnings of $1.36 per share. 

Still, there is room for optimism. 

In an earnings call, Novartis CEO Vasant Narasimhan said the company had achieved “solid operational performance over the past three years,” after revamping its strategy in 2018. Net sales from 2017 to 2020 have grown 5% annually while its Innovative Medicines division achieved a 35% growth rate in 2020. 

“We have a leading pipeline across 10 therapeutic areas [and], four advanced therapy platforms,” Narasimhan added. 

Novartis has enacted a series of cost-savings measures that has enabled the company to save $2 billion in cost over the past three years. T…

Read more
  • 0